Objective. In adults, autologous stem cell transplantation (ASCT ) has been described recently as a possible treatment for severe autoimmune disease refractory to conventional treatment. We report here the four first children with severe forms of juvenile chronic arthritis (JCA) treated with ASCT.
Juvenile chronic arthritis (JCA) is the most common with long-standing, severe JCA and polyarticular JCA treated with ASCT. autoimmune disease of childhood. Although the overall prognosis for most children with chronic arthritis is good, 5-10% of children with the systemic and poly-
Methods articular onset form are refractory to conventional
Patients: inclusion criteria therapy, consisting of combinations of non-steroidal anti-inflammatory drugs (NSAIDs) and immunoChildren with systemic chronic arthritis and polyarticusuppressive drugs such as methotrexate (MTX ) and lar chronic arthritis refractory to combinations of corticosteroids [1, 2] . These patients ultimately develop NSAIDs and immunosuppressive drugs such as MTX severe joint damage and loss of joint function, while the (high dose i.m.), cyclosporin (CsA) and corticosteroids, chronic use of immunosuppressive drugs leads to adverse and with a disease course longer than 1 yr, were included drug effects. To prevent severe joint damage and loss of in this study. joint function, new treatment strategies have been
Bone marrow harvesting and T-cell depletion developed [3] . Recently, we started a programme for the treatment of refractory JCA with autologous haemoHaemopoietic stem cells were obtained by conventional bone marrow aspiration under general anaesthesia withpoietic stem cell transplantation (ASCT ). We report here the 6-18 months follow-up in the first four children out priming. The graft was purged by two cycles of T-cell depletion with CD2 and CD3 antibodies [4] . Finally, a suspension of 0. Conditioning platelets (>20 × 109/l ). The number of T cells and in vitro mitogen responses normalized within 3-6 months. The conditioning regimen prior to ASCT included Within 2 weeks of ASCT, all patients showed a 4 days of antithymocyte globulin (ATG; IMTIX, Pasteur marked improvement, as measured by a decrease in Mérieux, France) in a dosage of 5 mg/kg daily from day joint swelling, pain and morning stiffness. ESR, −9 to −6, cyclophosphamide (Cy) in a dose of C-reactive protein (CRP) and haemoglobin (Hb) nor-50 mg/kg daily from day −5 to −2, and low-dose malized within 8 weeks. As measured by child health (4 Gy) single-fraction total body irradiation ( TBI ) on assessment questionnaires (CHAQ), EPM-ROM and day −1.
juvenile arthritis functional scores (JAFAS), there is a marked improvement in the functional activities of all Results children ( Table 2 ). Because of the longer follow-up in the first two patients, a favourable effect of ASCT on The clinical characteristics of the four patients are growth could already be seen in patients 1 and 2 ( Fig. 1 ). depicted in Table 1 . They were characterized by a refracIn general, the ASCT was well tolerated and there were tory chronic arthritis with the occurrence of erosions few complications (Table 3) . and growth disturbances of the joints. The duration of disease was >5 yr in all. Laboratory investigations showed increased erythrocyte sedimentation rate ( ESR) Discussion and a moderate to severe anaemia in all patients.
MTX and CsA were stopped prior to ASCT, and The effect of ASCT on signs and symptoms of chronic joint inflammation in four severely affected patients was corticosteroids were tapered and stopped 2 months after ASCT. NSAIDs were continued, but in all patients very favourable. The initial improvement could be explained by the immune suppression of the conditioning medication could be stopped completely within 6 months.
regimen, but the duration of the remission, even after recovery of the T cells and T-cell function, is indicative The recovery of the bone marrow took 20-30 days for neutrophils (>0.5 × 109/l ) and 16-35 days for the of an immune modulatory effect of ASCT. However, necessary to balance the risk of ASCT against conventional therapy with regard to outcome measurements and toxic side-effects of treatment. In this respect, ASCT still has to be regarded as an experimental therapy for children with severe refractory JCA and other autoimmune diseases. Recent experience in Europe indicates that ASCT for severe autoimmune disease carries a mortality risk of 10%. Therefore, we need consensus on inclusion criteria, conditioning regimen and graft handling. However, the short-term results of ASCT in our four patients are very promising and although the follow-up period is too short, the first impression is that ASCT could be an important weapon in the battle against refractory JCA.
